KNBIF (Kane Biotech) 3-Year EBITDA Growth Rate: 14.50% (As of Mar. 2026) — 28% Above Median


What is Kane Biotech 3-Year EBITDA Growth Rate?

Kane Biotech KNBIF -4.79% 3-Year EBITDA Growth Rate is 14.50% as of Mar. 2026, which is 28% above its 10-year median of 11.35. The stock has 6 warning signs investors should review. Among 1,136 Biotechnology companies, Kane Biotech ranks worse than 50.35% on this metric.

Kane Biotech's EBITDA per Share for the three months ended in Mar. 2026 was $-0.00.

During the past 3 years, the average EBITDA Per Share Growth Rate was 14.50% per year. During the past 5 years, the average EBITDA Per Share Growth Rate was 14.50% per year. During the past 10 years, the average EBITDA Per Share Growth Rate was 11.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Kane Biotech was 47.70% per year. The lowest was -38.70% per year. And the median was 11.35% per year.

Kane Biotech  (OTCPK:KNBIF) 3-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

Kane Biotech 3-Year EBITDA Growth Rate Related Terms

KNBIF vs VRTX, REGN, ALNY: 3-Year EBITDA Growth Rate Comparison

For the Biotechnology subindustry, Kane Biotech's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Kane Biotech 3-Year EBITDA Growth Rate vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Kane Biotech's 3-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where Kane Biotech's 3-Year EBITDA Growth Rate falls into.


Kane Biotech 3-Year EBITDA Growth Rate Calculation

This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

What does a 3-Year EBITDA Growth Rate of 14.50% mean?
Kane Biotech (KNBIF) has a 3-Year EBITDA Growth Rate of 14.50% as of Mar. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Kane Biotech and its competitors. This is 28% above median its historical median of 11.35. According to the industry distribution chart, Kane Biotech ranks #572 out of 1136 companies in the Biotechnology industry, placing it in the top 50.4%.
Is Kane Biotech's 3-Year EBITDA Growth Rate too high?
Kane Biotech's current 3-Year EBITDA Growth Rate of 14.50% is 28% above median its 10-year median of 11.35. The Biotechnology industry median 3-Year EBITDA Growth Rate is 14.85. Kane Biotech's value of 14.50% is 2.4% below this industry median. Based on the distribution chart, Kane Biotech ranks #572 out of 1136 companies in the Biotechnology industry, which is below the industry midpoint.
How does Kane Biotech's 3-Year EBITDA Growth Rate compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Kane Biotech ranks #572 out of 1136 companies for 3-Year EBITDA Growth Rate. This places Kane Biotech in the lower half of its industry. The industry median 3-Year EBITDA Growth Rate is 14.85. Kane Biotech's value of 14.50% is 2.4% below this benchmark. While the company's 10-year median is 11.35 vs. the industry median of 14.85, Kane Biotech has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Biotechnology company?
The median 3-Year EBITDA Growth Rate among Biotechnology companies is 14.85, based on 1,136 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Kane Biotech's current 3-Year EBITDA Growth Rate of 14.50% is 2.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Kane Biotech and its competitors. For the Biotechnology industry, the median 3-Year EBITDA Growth Rate is 14.85 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Kane Biotech's current 3-Year EBITDA Growth Rate is 14.50%, which is 28% above median its own 10-year median of 11.35. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kane Biotech stock overvalued right now?
Kane Biotech (KNBIF) has a current 3-Year EBITDA Growth Rate of 14.50%. The current 3-Year EBITDA Growth Rate is 14.50%, which is 28% above median its 10-year median of 11.35 and 2.4% below the Biotechnology industry median of 14.85. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Kane Biotech (KNBIF), the current 3-Year EBITDA Growth Rate is 14.50% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Kane Biotech Business Description

Other Exchanges KNE:Canada
Address 290-100 Innovation Drive, Winnipeg, MB, CAN, R3T 6G2
Kane Biotech Inc is a biotechnology company engaged in the research, development and commercialization of technologies and products that prevent and remove microbial biofilms. The company has a portfolio of biotechnologies, intellectual property and products developed by its own biofilm research expertise and acquired from research institutions. The company's operating segments are animal health and human health. It derives maximum revenue from Animal health segment.